Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
NCT05830058 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2026-01-05
Summary
This phase II trial tests the safety of positron emission tomography (PET) guided stereotactic body radiation therapy (SBRT) and how well it works to treat non-small cell lung cancer (NSCLC), melanoma, and renal cell carcinoma (RCC) that has up to 5 sites of progression (oligoprogression) compared to standard SBRT. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. A PET scan is an imaging test that looks at your tissues and organs using a small amount of a radioactive substance. It also checks for cancer and may help find cancer remaining in areas already treated. Using a PET scan for SBRT planning may help increase the dose of radiation given to the most resistant part of the cancer in patients with oligoprogressive NSCLC, melanoma, and RCC.
Conditions
- Lung Non-Small Cell Carcinoma
- Malignant Solid Neoplasm
- Melanoma
- Renal Cell Carcinoma
Interventions
- PROCEDURE
-
Biospecimen Collection
Undergo blood collection
- PROCEDURE
-
Computed Tomography
Undergo CT or PET/CT
- PROCEDURE
-
Positron Emission Tomography
Undergo PET
- OTHER
-
Questionnaire Administration
Ancillary studies
- RADIATION
-
Stereotactic Body Radiation Therapy
Undergo SBRT
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
City of Hope Medical Center
lead OTHER
Principal Investigators
-
Arya Amini · City of Hope Medical Center
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-11-29
- Primary Completion
- 2027-02-03
- Completion
- 2027-02-03
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer
NCT02206334 ·Status: COMPLETED ·Phase: PHASE1
-
Single Ultra-high Dose Stereotactic Body Radiation Therapy for Early Lung Cancer
NCT05802654 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Dz Control on PD-1/PDL-1 Tx
NCT03220854 ·Status: COMPLETED ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
NCT01185639 ·Status: COMPLETED ·Phase: NA
-
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
NCT02880319 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Stereotactic Radiotherapy With Different Fractionation Modes for the Early Lung Cancer
NCT05802641 ·Status: UNKNOWN
-
MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer
NCT02582931 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT05837767 ·Status: RECRUITING ·Phase: NA
-
Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
NCT06014827 ·Status: RECRUITING ·Phase: PHASE2
-
Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
NCT00551369 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Stereotactic Body Radiotherapy (SBRT) and Surgical Stabilization for People With Cancer That Has Spread to the Bone
NCT05038124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT01345851 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer
NCT02306954 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Phase I/II Trial of Stereotactic Body Radiation Therapy
NCT00591838 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System
NCT02067858 ·Status: TERMINATED ·Phase: NA
-
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NCT06686771 ·Status: RECRUITING ·Phase: PHASE3
-
A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer
NCT05138900 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
NCT01525446 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect
NCT03825510 ·Status: COMPLETED ·Phase: PHASE2
-
A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy
NCT06859801 ·Status: RECRUITING
-
To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors
NCT02410174 ·Status: TERMINATED ·Phase: PHASE1
-
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
NCT06549478 ·Status: RECRUITING ·Phase: PHASE1
-
A Trial to Improve Quality of Life With Stereotactic Body Radiotherapy for Patients With Painful Bone Metastases
NCT03831243 ·Status: COMPLETED ·Phase: NA
-
Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow
NCT02145286 ·Status: UNKNOWN ·Phase: NA
-
Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer
NCT02950337 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA